The Effect of Magnesium Supplement on the sFlt-1 Level (soluble fms-like tyrosine kinase-1) in Pregnant Women

The Effect of Magnesium Supplement on the sFlt-1 Level (soluble fms-like tyrosine kinase-1) in Pregnant Women: A Double-Blind Randomized Control Trial

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20200101045977N1

Enrollment

Registered

2020-01-24

Start date

2020-01-21

Completion date

Unknown

Last updated

2020-02-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

neonatal weight.

Interventions

Intervention 1: Intervention group: Participants in the intervention group will consume a 200 mg magnesium tablet of vitafit along with a multi-mineral tablet of Alhavi containing 100 mg of magnesium,

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Singleton pregnancy gestational age between 12-14 weeks

Exclusion criteria

Exclusion criteria: History of renal or cardiac disease, chronic hypertension or severe anemia, acute pancreatitis Pregnancy-related anomalies in the present and past pregnancies History of pre-eclampcia, pre-term labor, recurrent abortion or IUGR

Design outcomes

Primary

Measure	Time frame
SFlt-1 Level (soluble fms-like tyrosine kinase-1). Timepoint: 24-26 weeks and 34-36 weeks of gestational age and 24 hours after delivery. Method of measurement: Blood sample.	—

Secondary

Measure	Time frame
Magnesium level. Timepoint: 24-26 weeks and 34-36 weeks of gestational age and 24 hours after delivery. Method of measurement: Blood sample.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMaryam Abbasi

Mashhad University of Medical Sciences

abbasidm961@mums.ac.ir+98 51 3859 1511

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026